Alexza at outperform by RBC

RBC Capital Markets analyst Jason Kantor rated Alexza Pharmaceuticals, Inc. at outperform, above average risk, on news that the company began a phase 2a trial for AZ-004 in acute agitation in schizophrenia. In its first six months as a public company, Alexza has started four clinical trials for four separate and proprietary drugs. These trials set the stage for robust clinical news flow over the next six to 12 months. Shares of the Palo Alto, Calif.-based development-stage company were up 13 cents, or 1.86%, at $7.13. (Nasdaq: ALXA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.